# 60 Degrees Pharmaceuticals, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/60 Degrees Pharmaceuticals, Inc).

## Overview

60 Degrees Pharmaceuticals, Inc. (60P) is a U.S.-based specialty pharmaceutical company focused on infectious diseases, with a commercial malaria prevention product and a development pipeline targeting additional vector-borne, fungal, and viral indications. Its marketed product, Arakoda® (tafenoquine regimen), has been sold since late 2019 and is distributed primarily through third-party logistics and large pharmaceutical wholesalers, with significant rebates and discounts across the U.S. channel. The company also uses alternative supply routes (e.g., importing Kodatef with FDA approval during a packaging-related shortage) to maintain patient access. Beyond Arakoda, 60P is advancing programs based on tafenoquine, celgosivir, and botanical extracts from Australian chestnut trees, reflecting a strategy of lifecycle expansion and pipeline optionality in infectious disease prevention and treatment.

## Products & services

• Arakoda® (tafenoquine regimen) malaria prophylaxis
• Kodatef (imported supply to mitigate Arakoda shortages)
• Tafenoquine-based lifecycle and new product programs
• Celgosivir development programs (viral disease focus)
• Botanical extracts from Australian chestnut trees (R&D)
• Infectious disease R&D (vector-borne, fungal, viral)

- **Arakoda® (commercial product)** (85%) — U.S. and ex-U.S. sales of Arakoda malaria prevention via wholesalers/3PL and related channel programs.
- **Kodatef (commercial/bridging supply)** (5%) — Imported product supply used to serve patients during Arakoda packaging/availability disruptions.
- **Tafenoquine lifecycle & new indications (pipeline)** (5%) — Development of new products containing the Arakoda regimen of tafenoquine and other tafenoquine-based programs.
- **Celgosivir programs (pipeline)** (3%) — R&D programs using celgosivir for infectious disease applications, including viral diseases.
- **Botanical extract programs (pipeline)** (2%) — R&D programs using botanical extracts from Australian chestnut trees for infectious disease-related therapies.

- Arakoda® (tafenoquine regimen) malaria prophylaxis
- Kodatef (imported supply to mitigate Arakoda shortages)
- Tafenoquine-based lifecycle and new product programs
- Celgosivir development programs (viral disease focus)
- Botanical extracts from Australian chestnut trees (R&D)
- Infectious disease R&D (vector-borne, fungal, viral)

## Customers

60P’s near-term revenue is driven by sales of Arakoda to resellers and distribution partners rather than direct-to-patient sales. In the U.S., product flows through a third-party logistics (3PL) partner into large pharmaceutical distributors and then to pharmacies and dispensaries, with pharmacy benefit managers (PBMs) influencing patient access through formulary coverage and rebate-driven discounts. The company also uses specialty channels such as Infuserve America to supply patients, including during periods when standard commercial packaging was temporarily unavailable. Outside the U.S., the company sells via distributors in markets such as Australia and Europe, where profit-sharing arrangements can affect net economics per box sold. Customer concentration can be meaningful because a small number of distributors and channel partners can account for a large share of net product sales in a given period.

- **U.S. wholesalers / large pharmaceutical distributors** (primary) — Purchase Arakoda for downstream distribution to pharmacies/dispensaries; economics include distributor rebates and channel fees.
- **U.S. specialty access channel (Infuserve America)** (secondary) — Supplies patients when standard channels are constrained (e.g., packaging shortage) and can involve higher out-of-pocket/cash-pay dynamics.
- **Pharmacy benefit managers (PBMs) and covered lives ecosystem** (primary) — Influence utilization through formulary placement and patient discounts; rebates (30%–41.25% cited) materially affect net revenue.
- **Ex-U.S. distributors (Australia, Europe)** (secondary) — Buy product for local markets; certain foreign sales are subject to profit-sharing agreements affecting net realized revenue.

- U.S. pharmaceutical distributors buying Arakoda for retail/pharmacy channels
- 3PL partner handling title transfer and logistics for U.S. supply chain
- Pharmacies and dispensaries purchasing to serve travelers/at-risk patients
- Pharmacy benefit managers enabling coverage; rebates drive net pricing
- Infuserve America channel supplying patients (incl. cash-pay dynamics)
- Australian distributor purchasing Kodatef/Arakoda for local demand
- European resellers/distributors under profit-sharing arrangements

## Geography

The company is headquartered in the United States and generates most product revenue from U.S. commercial distribution of Arakoda. It also sells abroad, including through distributors in Australia and Europe, and notes that foreign sales can be subject to profit-sharing arrangements that change the net economics versus U.S. sales. Operationally, the business relies on a U.S.-centric supply chain model involving a 3PL partner, large U.S. distributors, and PBM-linked access pathways. Management notes that foreign operations are small relative to U.S. operations, which has made foreign currency translation effects minor in recent periods. Geographic mix matters primarily through channel structure (rebates/discounts) and the ability to maintain supply continuity across regions.

- United States is the core commercial market for Arakoda sales
- Australia sales occur via an Australian distributor (Kodatef noted)
- Europe sales occur via resellers/distributors with profit-sharing terms
- Foreign operations are small vs U.S.; FX translation impact described as minor
- U.S. distribution depends on 3PL + major wholesalers + PBM access pathways
- Supply disruptions in one market can be mitigated via imports/alternate channels

## Strategy

60P’s strategy centers on expanding and stabilizing its Arakoda commercial franchise while using it as a platform for broader infectious-disease development. Near-term execution priorities include maintaining reliable supply and packaging formats in the commercial channel, as evidenced by the transition to a new 8-count bottle and temporary use of imported Kodatef to mitigate shortages. The company is also advancing a pipeline spanning vector-borne, fungal, and viral diseases using three stated product approaches: Arakoda-regimen products, tafenoquine-based products, and celgosivir/botanical-extract programs. Given limited liquidity runway disclosed in filings, financing strategy (ATM usage, offerings, warrants) remains intertwined with operating plans and the pace of clinical development. Overall, the company’s competitive position depends on channel access (PBMs/wholesalers), lifecycle management of tafenoquine-based assets, and disciplined capital allocation to pipeline programs.

- **Stabilize Arakoda commercial supply and packaging formats** (short-term) — Channel availability directly drives unit volumes and net sales; shortages reduce pharmacy/dispensary throughput.
- **Expand infectious disease pipeline around tafenoquine and new modalities** (medium-term) — Pipeline breadth provides additional shots on goal beyond a single marketed product and supports long-term value creation.
- **Maintain access to capital to fund operations and clinical development** (short-term) — Management disclosed limited projected viability without additional raises; funding affects development pace and commercialization support.

- Defend and grow Arakoda demand through U.S. channel execution
- Improve supply reliability via packaging validation and format changes
- Use Kodatef imports/alternate channels to bridge commercial shortages
- Advance tafenoquine lifecycle programs beyond current malaria use
- Develop celgosivir and botanical extract programs for infectious diseases
- Secure funding via ATM and equity/warrant offerings to extend runway

## Risks

60P faces concentration and channel-pricing risk because Arakoda sales flow through a small number of distributors, a 3PL partner, and PBM arrangements where rebates can be large and variable, materially impacting net revenue. Operational execution risk is elevated given prior supply disruption tied to packaging validation delays, which reduced unit volumes and required mitigation via imported product and alternative distribution. As a small specialty pharma company, it also carries clinical and regulatory risk across its infectious-disease pipeline, where development timelines and outcomes are uncertain and may require additional capital. Financing and market-structure risks are prominent, including dilution from warrant exercises and the possibility of Nasdaq delisting if continued listing requirements (e.g., minimum bid price) are not met. Typical industry risks—manufacturing quality, product liability, competition from alternative prophylaxis/treatments, and inventory expiry/write-downs—can also affect profitability and continuity of supply.

- **Dilution from warrant exercises issued in July 2025 offering** [high] — Pre-funded and Series A warrants could add substantial shares, diluting existing holders and pressuring share price.
- **Nasdaq continued listing compliance (minimum bid price) and delisting** [high] — Delisting would likely reduce liquidity and could increase cost of capital and limit investor access.
- **Commercial supply disruption from packaging validation delays** [medium] — A shortage of Arakoda 16-ct boxes reduced sales volume and required mitigation via Kodatef importation and new packaging.

- High rebates/discounts (PBMs, wholesalers, 3PL) pressure net pricing
- Customer/channel concentration in a few distributors and partners
- Supply disruption risk from packaging/manufacturing validation delays
- Inventory expiry and write-down risk for time-sensitive pharma stock
- Pipeline clinical/regulatory failure risk in infectious disease programs
- Ongoing funding need; inability to raise capital could constrain plans
- Equity dilution risk from large warrant overhang
- Nasdaq listing compliance risk (minimum bid price) and delisting impact

## Accounting

Revenue is recognized under ASC 606 when control transfers to customers, and for 60P this is tied to distribution mechanics (e.g., when its 3PL partner transfers product into its title model), making cut-off and channel timing important for quarterly comparisons. Reported net product revenue is highly sensitive to estimates of variable consideration, including significant rebates and discounts to the 3PL partner, wholesalers, and PBMs, which require judgment and can create volatility in net sales. Cost of revenue includes manufacturing, shipping, serialization, and inventory write-downs due to expiration, so inventory management and obsolescence assumptions can affect gross margin. The company also highlights the use of estimates across the financial statements, which is particularly relevant for accruals, contingent milestone payments (not included in contractual obligations), and any valuation-related judgments. Given reliance on equity and warrant financing, investors should also monitor accounting for warrants and other equity-linked instruments (classification and fair value where applicable) as it can affect reported earnings and equity.

- **ASC 606 revenue recognition and variable consideration** — Affects net sales, receivables/contract liabilities, and period-to-period comparability
- **Inventory valuation and expiry-related write-downs** — Affects gross margin and can create quarter-to-quarter volatility

- ASC 606: revenue recognized when control transfers via 3PL title model
- Net sales depend on estimating rebates/discounts (PBMs up to ~41.25%)
- Variable consideration judgments can shift revenue between periods
- Cost of revenue includes serialization and inventory expiry write-downs
- Contingent milestone payments are excluded from contractual obligations
- Equity-linked financing (warrants) can add valuation/classification complexity

---

*Last updated: 2026-09-24T11:54:37.948130+00:00*